EyePoint Pharmaceuticals (EYPT) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart Transcripts

EYPT Stock Forecast

EyePoint Pharmaceuticals stock forecast is as follows: an average price target of $26.00 (represents a 211.38% upside from EYPT’s last price of $8.35) and a rating consensus of 'Buy', based on 6 wall street analysts offering a 1-year stock forecast.

EYPT Price Target

The average price target for EyePoint Pharmaceuticals (EYPT) is $26.00 based on 1-year price targets from 6 Wall Street analysts in the past 3 months, with a price target range of $30.00 to $22.00. This represents a potential 211.38% upside from EYPT's last price of $8.35.

EYPT Analyst Ratings

Buy

According to 6 Wall Street analysts, EyePoint Pharmaceuticals's rating consensus is 'Buy'. The analyst rating breakdown for EYPT stock is 0 'Strong Buy' (0.00%), 6 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

EyePoint Pharmaceuticals Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Nov 11, 2024	Yi Chen	H.C. Wainwright	$22.00	$11.59	89.90%	163.47%
May 13, 2024	Yi Chen	H.C. Wainwright	$30.00	$12.17	146.51%	259.28%
May 07, 2024	Graig Suvannavejh	Mizuho Securities	$30.00	$11.20	167.86%	259.28%
Aug 04, 2022	-	H.C. Wainwright	$25.00	$10.22	144.62%	199.40%

Row per page

Go to

The latest EyePoint Pharmaceuticals stock forecast, released on Nov 11, 2024 by Yi Chen from H.C. Wainwright, set a price target of $22.00, which represents a 89.90% increase from the stock price at the time of the forecast ($11.59), and a 163.47% increase from EYPT last price ($8.35).

EyePoint Pharmaceuticals Price Target by Period

	1M	3M	12M
# Anlaysts	1	1	3
Avg Price Target	$22.00	$22.00	$27.33
Last Closing Price	$8.35	$8.35	$8.35
Upside/Downside	163.47%	163.47%	227.31%

In the current month, the average price target of EyePoint Pharmaceuticals stock is $22.00, according to 1 Wall Street analyst offering twelve months forecast. The average price target represents a 163.47% increase as opposed to EyePoint Pharmaceuticals's last price of $8.35. This month's average price target is down 0.00% compared to last quarter, and down -19.50% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Oct 28, 2024	Guggenheim	Buy	Buy	Hold
Oct 28, 2024	Laidlaw	Buy	Buy	Hold
Aug 28, 2024	Jefferies	-	Buy	Initialise
Aug 13, 2024	Chardan Capital	Underperform	Underperform	Hold
Aug 13, 2024	J.P. Morgan	Buy	Buy	Hold
Jun 27, 2024	H.C. Wainwright	Buy	Buy	Hold
Jun 26, 2024	Laidlaw	Buy	Buy	Hold
May 13, 2024	H.C. Wainwright	Buy	Buy	Hold
May 07, 2024	Chardan Capital	Underperform	Underperform	Hold
May 07, 2024	Mizuho Securities	Buy	Buy	Hold

Row per page

Go to

EyePoint Pharmaceuticals's last stock rating was published by Guggenheim on Oct 28, 2024. The company gave EYPT a "Buy" rating, the same as its previous rate.

EyePoint Pharmaceuticals Financial Forecast

EyePoint Pharmaceuticals Revenue Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17
Revenue	-	-	-	-	-	-	-	-	-	-	$9.11M	$7.68M	$10.53M	$10.01M	$11.56M	$9.29M	$11.54M	$9.06M	$9.01M	$7.32M	$7.13M	$15.70M	$4.12M	$7.49M	$8.63M	$2.51M	$7.21M	$2.01M	$928.00K	$590.00K
Avg Forecast	$1.82M	$1.77M	$6.60M	$6.78M	$10.57M	$10.40M	$10.63M	$9.91M	$8.90M	$7.86M	$79.10M	$7.60M	$10.40M	$10.93M	$10.86M	$9.89M	$9.79M	$9.88M	$8.71M	$7.89M	$18.29M	$13.32M	$3.79M	$7.25M	$7.18M	$3.93M	$6.69M	$3.39M	$806.00K	$590.00K
High Forecast	$3.17M	$3.08M	$11.46M	$12.45M	$17.92M	$10.56M	$10.63M	$9.91M	$14.67M	$7.86M	$137.39M	$13.19M	$18.07M	$10.93M	$10.86M	$9.89M	$9.79M	$9.88M	$8.71M	$7.89M	$18.29M	$13.32M	$3.79M	$7.25M	$7.18M	$3.93M	$6.69M	$3.39M	$967.20K	$708.00K
Low Forecast	$790.07K	$768.42K	$2.86M	$1.09M	$5.76M	$10.25M	$10.63M	$9.90M	$705.37K	$7.86M	$34.24M	$3.29M	$4.50M	$10.93M	$10.86M	$9.89M	$9.79M	$9.88M	$8.71M	$7.89M	$18.29M	$13.32M	$3.79M	$7.25M	$7.18M	$3.93M	$6.69M	$3.39M	$644.80K	$472.00K
# Analysts	1	1	1	3	7	3	3	4	7	5	6	3	2	2	2	2	3	4	5	6	10	10	10	10	9	9	9	9	20	17
Surprise %	-	-	-	-	-	-	-	-	-	-	0.12%	1.01%	1.01%	0.92%	1.06%	0.94%	1.18%	0.92%	1.03%	0.93%	0.39%	1.18%	1.09%	1.03%	1.20%	0.64%	1.08%	0.59%	1.15%	1.00%

EyePoint Pharmaceuticals's average Quarter revenue forecast for Sep 23 based on 5 analysts is $7.86M, with a low forecast of $7.86M, and a high forecast of $7.86M. EYPT's average Quarter revenue forecast represents a -13.63% decrease compared to the company's last Quarter revenue of $9.11M (Jun 23).

EyePoint Pharmaceuticals EBITDA Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17
# Analysts	1	1	1	3	7	3	3	4	7	5	6	3	2	2	2	2	3	4	5	6	10	10	10	10	9	9	9	9	20	17
EBITDA	-	-	-	-	-	-	-	-	-	-	$-22.76M	$-20.35M	$-21.77M	$-17.14M	$-18.24M	$-17.53M	$-17.35M	$-14.61M	$-7.95M	$-10.25M	$-12.97M	$-1.29M	$-10.47M	$-10.74M	$-7.97M	$-13.23M	$-9.25M	$-17.56M	$-6.93M	$-4.93M
Avg Forecast	$-1.82M	$-1.77M	$-6.60M	$-6.78M	$-10.57M	$-10.40M	$-10.63M	$-17.26M	$-8.90M	$-7.86M	$-79.10M	$-18.46M	$-5.89M	$-10.93M	$-10.86M	$-19.74M	$-9.79M	$-9.88M	$-8.71M	$-9.36M	$-18.29M	$-13.32M	$-3.79M	$-9.67M	$-7.18M	$-3.93M	$-6.69M	$-11.04M	$-5.87M	$-4.93M
High Forecast	$-790.07K	$-768.42K	$-2.86M	$-1.09M	$-5.76M	$-10.25M	$-10.63M	$-13.81M	$-705.37K	$-7.86M	$-34.24M	$-14.77M	$-4.71M	$-10.93M	$-10.86M	$-15.80M	$-9.79M	$-9.88M	$-8.71M	$-7.49M	$-18.29M	$-13.32M	$-3.79M	$-7.73M	$-7.18M	$-3.93M	$-6.69M	$-8.83M	$-4.69M	$-3.95M
Low Forecast	$-3.17M	$-3.08M	$-11.46M	$-12.45M	$-17.92M	$-10.56M	$-10.63M	$-20.71M	$-14.67M	$-7.86M	$-137.39M	$-22.15M	$-7.06M	$-10.93M	$-10.86M	$-23.69M	$-9.79M	$-9.88M	$-8.71M	$-11.23M	$-18.29M	$-13.32M	$-3.79M	$-11.60M	$-7.18M	$-3.93M	$-6.69M	$-13.24M	$-7.04M	$-5.92M
Surprise %	-	-	-	-	-	-	-	-	-	-	0.29%	1.10%	3.70%	1.57%	1.68%	0.89%	1.77%	1.48%	0.91%	1.10%	0.71%	0.10%	2.76%	1.11%	1.11%	3.36%	1.38%	1.59%	1.18%	1.00%

undefined analysts predict EYPT's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than EyePoint Pharmaceuticals's previous annual EBITDA (undefined) of $NaN.

EyePoint Pharmaceuticals Net Income Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17
# Analysts	1	1	1	3	7	3	3	4	7	5	6	3	2	2	2	2	3	4	5	6	10	10	10	10	9	9	9	9	20	17
Net Income	-	-	-	-	-	-	-	-	-	-	$-22.92M	$-21.59M	$-64.15M	$-18.44M	$-19.60M	$-22.54M	$-20.82M	$-16.70M	$-10.01M	$-12.28M	$-15.47M	$-3.80M	$-12.95M	$-13.17M	$-10.41M	$-15.65M	$-11.50M	$-19.24M	$-6.98M	$-5.14M
Avg Forecast	$-37.79M	$-36.59M	$-32.12M	$-31.25M	$-27.10M	$-29.72M	$-27.47M	$-18.97M	$-26.48M	$-27.09M	$75.36M	$-20.29M	$-6.13M	$-36.00M	$-27.84M	$-21.70M	$-28.09M	$-21.39M	$-23.94M	$-11.21M	$-3.64M	$-15.96M	$-55.87M	$-11.86M	$-62.52M	$-73.16M	$-63.85M	$-12.09M	$-5.90M	$-5.14M
High Forecast	$-9.93M	$-9.62M	$-8.44M	$-25.95M	$-19.53M	$-7.81M	$-7.22M	$-15.18M	$-17.65M	$-7.12M	$147.55M	$-16.23M	$-4.90M	$-36.00M	$-27.84M	$-17.36M	$-28.09M	$-21.39M	$-23.94M	$-8.97M	$-3.64M	$-15.96M	$-55.87M	$-9.49M	$-62.52M	$-73.16M	$-63.85M	$-9.67M	$-4.72M	$-4.11M
Low Forecast	$-73.99M	$-71.65M	$-62.90M	$-36.56M	$-33.40M	$-58.20M	$-53.79M	$-22.76M	$-33.54M	$-53.04M	$19.80M	$-24.35M	$-7.35M	$-36.00M	$-27.84M	$-26.04M	$-28.09M	$-21.39M	$-23.94M	$-13.45M	$-3.64M	$-15.96M	$-55.87M	$-14.23M	$-62.52M	$-73.16M	$-63.85M	$-14.51M	$-7.09M	$-6.17M
Surprise %	-	-	-	-	-	-	-	-	-	-	-0.30%	1.06%	10.47%	0.51%	0.70%	1.04%	0.74%	0.78%	0.42%	1.10%	4.25%	0.24%	0.23%	1.11%	0.17%	0.21%	0.18%	1.59%	1.18%	1.00%

EyePoint Pharmaceuticals's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. EYPT's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

EyePoint Pharmaceuticals SG&A Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17
# Analysts	1	1	1	3	7	3	3	4	7	5	6	3	2	2	2	2	3	4	5	6	10	10	10	10	9	9	9	9	20	17
SG&A	-	-	-	-	-	-	-	-	-	-	$14.34M	$14.98M	$14.41M	$15.23M	$15.44M	$15.24M	$17.03M	$13.43M	$11.84M	$10.77M	$11.59M	$11.06M	$10.88M	$12.48M	$11.55M	$12.14M	$12.10M	$11.92M	$2.28M	$2.43M
Avg Forecast	$2.81M	$2.73M	$10.16M	$10.43M	$16.27M	$16.02M	$16.37M	$15.25M	$13.71M	$12.11M	$121.79M	$11.69M	$2.62M	$16.77M	$16.67M	$15.18M	$15.03M	$15.17M	$13.37M	$12.11M	$28.08M	$20.44M	$5.82M	$11.13M	$11.01M	$6.04M	$10.27M	$5.20M	$1.24M	$905.58K
High Forecast	$4.88M	$4.75M	$17.65M	$19.17M	$27.59M	$16.25M	$16.37M	$15.26M	$22.59M	$12.11M	$211.54M	$20.31M	$3.14M	$16.77M	$16.67M	$15.18M	$15.03M	$15.17M	$13.37M	$12.11M	$28.08M	$20.44M	$5.82M	$11.13M	$11.01M	$6.04M	$10.27M	$5.20M	$1.48M	$1.09M
Low Forecast	$1.22M	$1.18M	$4.40M	$1.68M	$8.87M	$15.79M	$16.37M	$15.24M	$1.09M	$12.11M	$52.72M	$5.06M	$2.10M	$16.77M	$16.67M	$15.18M	$15.03M	$15.17M	$13.37M	$12.11M	$28.08M	$20.44M	$5.82M	$11.13M	$11.01M	$6.04M	$10.27M	$5.20M	$989.69K	$724.47K
Surprise %	-	-	-	-	-	-	-	-	-	-	0.12%	1.28%	5.50%	0.91%	0.93%	1.00%	1.13%	0.89%	0.89%	0.89%	0.41%	0.54%	1.87%	1.12%	1.05%	2.01%	1.18%	2.29%	1.84%	2.68%

EyePoint Pharmaceuticals's average Quarter SG&A projection for Sep 23 is $12.11M, based on 5 Wall Street analysts, with a range of $12.11M to $12.11M. The forecast indicates a -15.59% fall compared to EYPT last annual SG&A of $14.34M (Jun 23).

EyePoint Pharmaceuticals EPS Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17
# Analysts	1	1	1	3	7	3	3	4	7	5	6	3	2	2	2	2	3	4	5	6	10	10	10	10	9	9	9	9	20	17
EPS	-	-	-	-	-	-	-	-	-	-	$-0.61	$-0.58	$-1.72	$-0.49	$-0.53	$-0.60	$-0.64	$-0.58	$-0.35	$-0.50	$-1.07	$-0.30	$-1.04	$-1.14	$-0.98	$-1.46	$-1.08	$-2.02	$-1.53	$-1.50
Avg Forecast	$-0.69	$-0.67	$-0.59	$-0.57	$-0.50	$-0.55	$-0.50	$-0.40	$-0.49	$-0.50	$1.38	$-0.68	$-0.61	$-0.68	$-0.52	$-0.58	$-0.53	$-0.40	$-0.45	$-0.49	$-0.07	$-0.30	$-1.05	$-0.95	$-1.18	$-1.38	$-1.20	$-1.37	$-0.11	$-0.15
High Forecast	$-0.18	$-0.18	$-0.16	$-0.48	$-0.36	$-0.14	$-0.13	$-0.11	$-0.32	$-0.13	$2.71	$-0.18	$-0.16	$-0.68	$-0.52	$-0.58	$-0.53	$-0.40	$-0.45	$-0.49	$-0.07	$-0.30	$-1.05	$-0.95	$-1.18	$-1.38	$-1.20	$-1.37	$-0.09	$-0.12
Low Forecast	$-1.36	$-1.32	$-1.16	$-0.67	$-0.61	$-1.07	$-0.99	$-0.79	$-0.62	$-0.97	$0.36	$-1.33	$-1.19	$-0.68	$-0.52	$-0.58	$-0.53	$-0.40	$-0.45	$-0.49	$-0.07	$-0.30	$-1.05	$-0.95	$-1.18	$-1.38	$-1.20	$-1.37	$-0.13	$-0.18
Surprise %	-	-	-	-	-	-	-	-	-	-	-0.44%	0.85%	2.82%	0.72%	1.01%	1.04%	1.21%	1.44%	0.78%	1.01%	15.66%	1.00%	0.99%	1.20%	0.83%	1.06%	0.90%	1.48%	13.91%	10.00%

According to undefined Wall Street analysts, EyePoint Pharmaceuticals's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to EYPT previous annual EPS of $NaN (undefined).

EyePoint Pharmaceuticals Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
VIRX	Viracta Therapeutics	$0.15	$8.00	5233.33%	Buy
ALXO	ALX Oncology	$1.29	$24.50	1799.22%	Buy
XFOR	X4 Pharmaceuticals	$0.37	$3.67	891.89%	Buy
CABA	Cabaletta Bio	$1.87	$16.33	773.26%	Buy
RVPH	Reviva Pharmaceuticals	$1.24	$10.00	706.45%	Buy
IPHA	Innate Pharma	$1.70	$10.00	488.24%	Buy
SLS	SELLAS Life Sciences Group	$1.22	$7.00	473.77%	Buy
BMEA	Biomea Fusion	$6.38	$22.75	256.58%	Buy
EYPT	EyePoint Pharmaceuticals	$8.35	$26.00	211.38%	Buy
ABOS	Acumen Pharmaceuticals	$2.31	$7.00	203.03%	Buy
DAWN	Day One Biopharmaceuticals	$13.34	$38.80	190.85%	Buy
TERN	Terns Pharmaceuticals	$5.71	$14.25	149.56%	Buy
MREO	Mereo BioPharma Group	$3.68	$6.75	83.42%	Buy
HOOK	HOOKIPA Pharma	$2.30	$3.00	30.43%	Buy

EYPT Forecast FAQ

Is EyePoint Pharmaceuticals a good buy?

Yes, according to 6 Wall Street analysts, EyePoint Pharmaceuticals (EYPT) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 6 'Buy' recommendations, accounting for 100.00% of EYPT's total ratings.

What is EYPT's price target?

EyePoint Pharmaceuticals (EYPT) average price target is $26 with a range of $22 to $30, implying a 211.38% from its last price of $8.35. The data is based on 6 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will EyePoint Pharmaceuticals stock go up soon?

According to Wall Street analysts' prediction for EYPT stock, the company can go up by 211.38% (from the last price of $8.35 to the average price target of $26), up by 259.28% based on the highest stock price target, and up by 163.47% based on the lowest stock price target.

Can EyePoint Pharmaceuticals stock reach $13?

EYPT's average twelve months analyst stock price target of $26 supports the claim that EyePoint Pharmaceuticals can reach $13 in the near future.

What is EyePoint Pharmaceuticals's current price target trend?

1 Wall Street analyst forecast a $22 price target for EyePoint Pharmaceuticals (EYPT) this month, up 163.47% from its last price of $8.35. Compared to the last 3 and 12 months, the average price target increased by 163.47% and increased by 227.31%, respectively.

What are EyePoint Pharmaceuticals's analysts' financial forecasts?

EyePoint Pharmaceuticals's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $41.51M (high $49.02M, low $36.55M), average EBITDA is $-48.867M (high $-40.455M, low $-59.82M), average net income is $-103M (high $-49.74M, low $-168M), average SG&A $63.92M (high $75.48M, low $56.27M), and average EPS is $-1.95 (high $-0.74, low $-3.457). EYPT's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $16.98M (high $30.17M, low $5.5M), average EBITDA is $-16.975M (high $-5.504M, low $-30.168M), average net income is $-138M (high $-53.934M, low $-245M), average SG&A $26.14M (high $46.45M, low $8.47M), and average EPS is $-2.53 (high $-0.991, low $-4.501).

Did the EYPT's actual financial results beat the analysts' financial forecasts?

Based on EyePoint Pharmaceuticals's last annual report (Dec 2022), the company's revenue was $41.4M, which missed the average analysts forecast of $42.08M by -1.61%. Apple's EBITDA was $-74.757M, beating the average prediction of $-47.419M by 57.65%. The company's net income was $-125M, beating the average estimation of $-91.674M by 35.82%. Apple's SG&A was $60.32M, beating the average forecast of $51.24M by 17.73%. Lastly, the company's EPS was $-3.34, beating the average prediction of $-2.388 by 39.87%. In terms of the last quarterly report (Jun 2023), EyePoint Pharmaceuticals's revenue was $9.1M, missing the average analysts' forecast of $79.1M by -88.49%. The company's EBITDA was $-22.761M, missing the average prediction of $-79.1M by -71.23%. EyePoint Pharmaceuticals's net income was $-22.92M, missing the average estimation of $75.36M by -130.42%. The company's SG&A was $14.34M, missing the average forecast of $121.79M by -88.22%. Lastly, the company's EPS was $-0.61, missing the average prediction of $1.38 by -144.08%